Anthropic CEO Dario Amodei said artificial intelligence could help cure most human diseases within five to 10 years, arguing that the industry must deliver real breakthroughs in medicine rather than rely on optimistic messaging.

Amodei made the comments in a post on X, responding to criticism that his public messaging has focused disproportionately on AI risks. He cited his 2024 essay "Machines of Loving Grace," which challenged skepticism about AI's potential in health and biology. He also referenced a June 2026 essay, "Policy on the AI Exponential," where he proposed streamlining Food and Drug Administration (FDA) processes to prevent regulatory delays for AI-accelerated drugs.

Personal Motivation and Industry Trust

Amodei linked his urgency to personal experience, noting his father died from Hepatitis C shortly before direct-acting antiviral drugs like sofosbuvir were developed. He stated these drugs could cure 95% of patients and likely would have cured his father.

He acknowledged that predicting cures for most diseases within five to 10 years may sound far-fetched to the public and biologists. However, he emphasized that Anthropic is rapidly increasing efforts in biology and medicine, expecting "early glimmers" of progress in coming months.

What the Numbers Show

The data highlights a divergence between public perception and industry action. Amodei noted that public skepticism reflects a broader crisis of trust in companies and governments. He argued that marketing campaigns promising future benefits are insufficient to counter this skepticism. Instead, he stated that actual cures, such as curing cancer, would be more meaningful than promises. He admitted that AI companies deserve criticism for not yet delivering on their biggest promises, placing the responsibility on the industry to produce tangible results.

Regulatory and Strategic Outlook

Amodei stressed that medical impact requires not just capable AI but also regulatory changes. He proposed ways to streamline FDA processes so that waves of AI-accelerated drugs are not unnecessarily slowed.

He intends to continue speaking honestly about both AI's potential benefits and risks. Amodei said credibility will ultimately come from tangible results rather than promises, and Anthropic will publicize achievements in biology and medicine when they materialize.

Anthropic CEO Dario Amodei has pushed back against criticism from investor Gavin Baker, arguing that carefully designed artificial intelligence regulations can limit the power of frontier labs without undermining competition or open-weight models. The debate centers on Baker's assertion that Amodei's public messaging suggests Anthropic might become the only private company in the world, a claim an Anthropic employee called "completely false."

Amodei addressed the controversy directly, stating that the choice between concentrating AI power in the hands of a few companies and governments versus distributing it widely is a "false choice." He argued that regulations can impose tougher requirements on frontier AI companies while giving smaller competitors more room to develop, potentially strengthening market competition.

Regulatory Stance and Public Messaging

Baker, managing partner and chief investment officer at Atreides Management, had appeared on the All-In podcast to voice concerns about Amodei's push for stricter AI regulation. Baker argued that concentrating powerful AI systems among a small group of companies and governments could be more dangerous than widely distributing the technology, citing Meta Platforms Inc. (NASDAQ: META) CEO Mark Zuckerberg's similar arguments.

Amodei disagreed with this framing, noting that he supports the Donald Trump administration's reported approach of pre-deployment testing for frontier AI models. He also supported testing advanced open-weight models, despite reports that the White House told major AI companies that open-weight models would be exempt from planned AI safety testing.

Regarding his public communications, Amodei rejected Baker's criticism that his messaging has been disproportionately negative toward AI. He stated that Anthropic has discussed both the risks and potential benefits of advanced AI, including major breakthroughs in medicine and biology. Amodei attributed the negative public perception of AI to a broader "crisis of trust" rather than his specific messaging.

Revenue Growth Context

The regulatory debate unfolds against a backdrop of significant financial growth for Anthropic. The company reportedly expects to generate $190 billion to $200 billion in revenue by 2028, a substantial increase from its roughly $47 billion annualized revenue run rate in May.

For the second quarter of 2026, Anthropic expects revenue of at least $10.9 billion, more than double the previous quarter. This rapid growth trajectory underscores the increasing financial stakes in the AI sector as companies navigate evolving regulatory landscapes.

What the Numbers Show

The divergence between Anthropic's rapid revenue growth and the ongoing regulatory debate highlights a critical tension in the AI industry. While the company's financial metrics show explosive expansion—from a $9 billion run rate at the end of 2025 to a projected $190 billion to $200 billion by 2028—the regulatory framework remains unsettled. Amodei's defense of targeted regulation for frontier models suggests that Anthropic views compliance not as a barrier to growth, but as a mechanism that could shape competitive dynamics in its favor by imposing heavier burdens on larger players while allowing smaller competitors space to develop.